Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial

Overview of attention for article published in Advances in Therapy, January 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 21 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 4,489 followers.

RT @AdvancesTherapy: Efficacy, tolerability and pharmacokinetic impact of #aprepitant in #sarcoma patients receiving #ifosfamide and #doxor…

Reply Repost Favourite

RT @AdvancesTherapy: Efficacy, tolerability and pharmacokinetic impact of #aprepitant in #sarcoma patients receiving #ifosfamide and #doxor…

Reply Repost Favourite

RT @AdvancesTherapy: Efficacy, tolerability and pharmacokinetic impact of #aprepitant in #sarcoma patients receiving #ifosfamide and #doxor…

Reply Repost Favourite

Efficacy, tolerability and pharmacokinetic impact of #aprepitant in #sarcoma patients receiving #ifosfamide and #doxorubicin for the of prevention of chemotherapy-induced nausea and vomiting (#CINV): https://t.co/SrOHMqpGvV https://t.co/rBOd2XkmEk

Reply Repost Favourite